Hypertensive Disorders in Pregnancy and the Risk of Subsequent Cardiovascular Disease.

Paediatr Perinat Epidemiol

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.

Published: September 2017

Background: Hypertensive disorders in pregnancy (HDP) have been shown to predict later risk of cardiovascular disease (CVD). However, previous studies have not accounted for subsequent pregnancies and their complications, which are potential confounders and intermediates of this association.

Methods: A cohort of 146 748 women with a first pregnancy was constructed using the Clinical Practice Research Datalink. HDP was defined using diagnostic codes, elevated blood pressure readings, or new use of an anti-hypertensive drug between 18 weeks' gestation and 6 weeks post-partum. The study outcomes were incident CVD and hypertension. Marginal structural Cox models (MSM) were used to account for time-varying confounders and intermediates. Time-fixed exposure defined at the first pregnancy was used in secondary analyses.

Results: A total of 997 women were diagnosed with incident CVD, and 6812 women were diagnosed with hypertension or received a new anti-hypertensive medication during the follow-up period. Compared with women without HDP, those with HDP had a substantially higher rate of CVD (hazard ratio (HR) 2.2, 95% confidence interval (CI) 1.7, 2.7). In women with HDP, the rate of hypertension was five times that of women without a HDP (HR 5.6, 95% CI 5.1, 6.3). With overlapping 95% CIs, the time-fixed analysis and the MSM produced consistent results for both outcomes.

Conclusions: Women with HDP are at increased risk of developing subsequent CVD and hypertension. Similar estimates obtained with the MSM and the time-fixed analysis suggests that subsequent pregnancies do not confound a first episode of HDP and later CVD.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ppe.12388DOI Listing

Publication Analysis

Top Keywords

women hdp
16
hypertensive disorders
8
disorders pregnancy
8
cardiovascular disease
8
hdp
8
subsequent pregnancies
8
confounders intermediates
8
incident cvd
8
cvd hypertension
8
women diagnosed
8

Similar Publications

Soluble Fms-like tyrosine kinase-1 polymorphisms associated with severe-spectrum hypertensive disorders of pregnancy.

Arch Gynecol Obstet

January 2025

Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90089, USA.

Background: sFLT-1 has been implicated in the pathogenesis of HDP. We aimed to examine the role of maternal and fetal polymorphisms in risk of HDP and severe-spectrum disease.

Methods: Cases of HDP (143) and controls (169) from mother-baby dyads were recruited at the Los Angeles County Women's and Children's Hospital (WCH).

View Article and Find Full Text PDF

The maternal body mass index and first-trimester placental (vascular) development.

Placenta

December 2024

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Electronic address:

Background: Maternal obesity is associated with maternal complications, including hypertensive disorders of pregnancy (HDP), and related fetal complications, such as fetal growth restriction. During pregnancy, the placenta is one of the key regulators of embryonic and fetal growth. Previous studies mainly investigated placental growth by measuring postpartum placental weight.

View Article and Find Full Text PDF

Hypertensive disorders of pregnancy (HDP) are significant global health issues. This study utilized data from the Global Burden of Disease Study 2021 to analyze trends in incidence, prevalence, and Disability-Adjusted Life Years (DALY) associated with HDP across 204 countries from 1990 to 2021. The analysis employed estimated annual percentage changes and an age-period-cohort model, stratifying data by age, year, geographical region, and sociodemographic index (SDI).

View Article and Find Full Text PDF

Background: Aspirin has proved its efficacy in reducing the rate of preeclampsia in singleton pregnancy, however, there is discrepancy about the efficient dosage that should be used. While some societies recommend daily 75-81mg, others recommend higher dosage (160mg). This discrepancy is due to the lack of randomized controlled studies that compare these two dosages.

View Article and Find Full Text PDF

Background: Cardiovascular disease (CVD) is the leading cause of death among women in America. Hypertensive disorders of pregnancy (HDP) negatively impact acute and long-term cardiovascular health, with approximately 16% of all pregnancies affected. With CVD 2-4 times more likely after HDP compared to normotensive pregnancies, effective interventions to promote cardiovascular health are imperative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!